KOBV-Portal

Treffer pro Seite

Treffer 1 - 1 | 1 Treffer

Alles auswählen Exportieren

Online-Ressource

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with 〉30% blasts

Dombret, Hervé ; Seymour, John F. ; Butrym, Aleksandra ; [weitere]

American Society of Hematology ; 2015

In: Blood Vol. 126, No. 3 ( 2015-07-16), p. 291-299

zur Merkliste hinzufügen auf der Merkliste

Details

In: Blood, American Society of Hematology, Vol. 126, No. 3 ( 2015-07-16), p. 291-299

Kurzfassung: Azacitidine increased median overall survival by 3.8 months vs current commonly used AML treatments (10.4 vs 6.5 months; P = .1009). Azacitidine safety in patients age ≥65 years with AML ( 〉 30% blasts) was consistent with its known safety profile in other trials.

Materialart: Online-Ressource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood-2015-01-621664

RVK:

XA 33000

RVK:

XA 10000

Sprache: Englisch

Verlag: American Society of Hematology

Publikationsdatum: 2015

ZDB Id: 1468538-3